Login/Sign Up
MRP ₹37106
(Inclusive of all Taxes)
₹1855.3 Cashback (5%)
Provide Delivery Location
Therapeutic Class
Country of origin
Manufacturer/Marketer address
We provide you with authentic, trustworthy and relevant information
Alcohol
Caution
Avoid alcohol consumption while on treatment with Pivikto 150 mg Tablet .
Pregnancy
Unsafe
Pivikto 150 mg Tablet should not be used during pregnancy. So, inform your doctor if you are pregnant or suspect pregnancy. You or your partner must use a reliable form of contraception to prevent pregnancy while taking these medications.
Breast Feeding
Caution
Lactating women should not breastfeed throughout Pivikto 150 mg Tablet treatment and for one week following the final dosage.
Driving
Caution
Pivikto 150 mg Tablet does not influence the ability to drive or use machines. However, go only if you are alert, as the Pivikto 150 mg Tablet may cause weakness or tiredness in some people.
Liver
Caution
Limited information is available. Inform your doctor before taking the Pivikto 150 mg Tablet if you have had a liver impairment/disorder history. Your doctor will prescribe only if the benefits outweigh the risks.
Kidney
Caution
No dose adjustment is recommended for patients with mild to moderate renal impairment (CLcr 30 to < 90 mL/min). The effect of severe renal impairment (CLcr < 30 mL/min) on alpelisib is unknown. So, inform your doctor before taking the Pivikto 150 mg Tablet if you have had a kidney impairment/disorder history. Your doctor will prescribe only if the benefits outweigh the risks.
Children
Unsafe
Safety and effectiveness in patients below the age of 18 years have not been established. Hence, use is not recommended.
About Pivikto 150 mg Tablet
Pivikto 150 mg Tablet belongs to a class of kinase inhibitors. It is used in conjunction with fulvestrant to treat postmenopausal women and men with hormone receptor (HR)-positive, HER2-negative, PIK3CA-mutated, advanced, or metastatic breast cancer.
Pivikto 150 mg Tablet contains Alpelisib. In breast cancers with a PIK3CA gene mutation, a protein called PI3K is involved in helping the cancer cells multiply and grow. By blocking the action of PI3K, Alpelisib helps stop the growth and spread of the cancer.
To treat your condition effectually, continue using Pivikto 150 mg Tablet for as long as your doctor has prescribed it. The most common side effects include rash, decreased appetite, weight loss, nausea, mouth sores, hair loss, tiredness and weakness, vomiting, changes in certain blood tests, allergic reactions, skin reactions, high blood sugar levels, lung problems, and diarrhea. You should talk to your doctor if you persistently experience these side effects.
Avoid taking Pivikto 150 mg Tablet if you are allergic to it. It is not recommended for use in pregnancy. Lactating women do not breastfeed during treatment with Pivikto 150 mg Tablet and for one week after the last dose. Alcohol should be avoided during treatment with this medicine. Safety and effectiveness in children have not been established.
Uses of Pivikto 150 mg Tablet
Medicinal Benefits
Pivikto 150 mg Tablet contains Alpelisib, which belongs to a class of kinase inhibitors. It is used in conjunction with fulvestrant to treat postmenopausal women and men with hormone receptor (HR)-positive, HER2-negative, PIK3CA-mutated, advanced, or metastatic breast cancer. In breast cancers with a PIK3CA gene mutation, a protein called PI3K is involved in helping the cancer cells multiply and grow. By blocking the action of PI3K, Alpelisib helps stop the growth and spread of the cancer.
Directions for Use
Side Effects of Pivikto 150 mg Tablet
Drug Warnings
It is not advised during pregnancy, nursing, or for children or young adults under 18. Before taking the Pivikto 150 mg Tablet , inform your doctor about all your medical conditions (especially lung infections, diarrhoea, diabetics, kidney or liver impairment), sensitivities or allergic conditions, and all medications you use. Consult your doctor right away if you become pregnant while taking Pivikto 150 mg Tablet . Exposure of an unborn child to this medication could cause congenital disabilities, so you should not become pregnant or father a child while on this medication. Effective birth control is required throughout treatment and at least one week after treatment. You should not breastfeed while taking this medication for two weeks after your last dose.
Drug-Drug Interactions
Login/Sign Up
Drug-Food Interactions
Login/Sign Up
Drug-Diseases Interactions
Login/Sign Up
Drug-Drug Interactions Checker List
Habit Forming
Special Advise
Diet & Lifestyle Advise

Have a query?